Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adrián García-Villa has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Carme Font

    Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain

    5 shared publications
  • Carmen Diaz-Pedroche

    Department of Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain

    3 shared publications
  • Carmen Díaz-Pedroche

    Department of Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain

    3 shared publications
  • Juan José Criado-Álvarez

    Gerencia de Atención Integrada de Talavera de la Reina, Servicio de Salud de Castilla-La Mancha, Spain; Faculty of Health Sciences, Universidad de Castilla-La Mancha, Talavera de la Reina, Spain

    3 shared publications
  • Mario Aramberri

    Department of Internal Medicine, Santa Marina Ospitalea, Bilbao, Spain

    3 shared publications
  • Mario Aramberri

    Department of Internal Medicine, Hospital de Galdakao-Usansolo, Galdakao, Spain

    3 shared publications

Latest Publications

  • Open Access

    Nutritional Risk in Patients Admitted to Medical Oncology Departments: Prevalence, Associated Factors and Clinical Outcomes in a Multicentre Prospective Study

    by Francisco Javier Teigell Muñoz, Laia Llobera Rius, Laura Medina Ortega, Pablo Villacé Gallego, Javier Marco-Hernández, Esther Paula Fernández Fernández, Anna Esquerrà Molas, Leyre Liesa Delgado, Luis Manuel Sáez Urán, Jesús González Olmedo, et al.

    Background/Objectives: Malnutrition and nutritional vulnerability are common in patients with cancer and are associated with adverse clinical outcomes, particularly among hospitalised patients. However, data specifically describing nutritional risk in patients admitted to medical oncology departments remain limited. This study aimed to estimate the prevalence of nutritional risk at hospital admission and to evaluate factors associated with nutritional risk and its clinical consequences. Methods: The REGIO registry is a national multicentre prospective cohort including adult patients with solid tumours admitted to medical oncology departments in 17 Spanish hospitals between February 2024 and January 2025. Nutritional risk was assessed within the first working day of hospitalisation using the Malnutrition Screening Tool (MST), with a score ≥ 2 indicating nutritional risk. Multivariable logistic regression models were used to identify factors associated with nutritional risk and its association with prolonged hospital stay and mortality. Results: A total of 1229 patients were included (median age 67.8 years; 59% male; 64% metastatic disease). Nutritional risk was identified in 53% of patients. In multivariable analysis, poorer functional status, tumour progression, recent exposure to cytotoxic chemotherapy, and tumour types with higher nutritional impact were independently associated with nutritional risk. Patients at nutritional risk had longer hospital stays (median 10 vs. 7 days; p < 0.001), a higher likelihood of prolonged hospitalisation (adjusted OR 1.38), and increased mortality at 30 days (adjusted OR 1.63) and 60 days after discharge (adjusted OR 1.53). Conclusions: In this large multicentre cohort, nutritional risk was highly prevalent and independently associated with worse clinical outcomes, supporting the clinical relevance of systematic nutritional screening at hospital admission in patients with cancer.


  • Anticoagulant therapy for cancer-associated splanchnic vein thrombosis: Outcomes during a one-year follow-up period

    by Adrian Garcia-Villa, Juan José Criado-Álvarez, María Carnevali, Mario Aramberri, Carme Font, Carmen Díaz-Pedroche


  • Open Access

    Anticoagulant Therapy for Cancer-Associated Splanchnic Vein Thrombosis: Outcomes During a One-Year Follow-Up Period

    by Adrian Garcia-Villa, Juan José Criado-Álvarez, María Carnevali, Mario Aramberri, Carme Font, Carmen Díaz-Pedroche

    IntroductionThe incidence of splanchnic vein thrombosis (SVT) in cancer patients has increased in recent years due to improved survival rates and the widespread use of scheduled radiological tests. However, studies describing the long-term prognosis and benefits of anticoagulant treatment are scarce. The objectives were to describe long-term prognosis and to compare outcomes based on anticoagulant treatment during a one-year follow-up.Material and MethodsThis was a retrospective observational study of consecutive patients hospitalized between 2015 and 2020 with a diagnosis of cancer-associated SVT either prior to admission or during hospitalization.ResultsThe study included 201 patients, with intra-abdominal tumors (78.2%) predominating, particularly pancreatic cancer (43.8%). Portal thrombosis (58.6%) was the most common type of SVT. Approximately 41.3% of cases received anticoagulant treatment at the diagnosis of SVT. The overall survival rate at 12 months was 39.7%. Anticoagulant therapy was associated with a significantly higher accumulated incidence of recanalization and bleeding. However, no differences were found in the survival and recurrence of thrombosis. Vascular invasion by tumor (OR 2.44; CI 95% 1.32-4.52) and the metastatic status of the oncological disease (OR 3.07; CI 95% 1.63-5.8) were predictive factors for death.ConclusionsSVT is a common complication in cancer patients, particularly in those with abdominal tumors. Vascular invasion by the tumor and metastatic status were negative prognostic factors. Anticoagulant treatment was associated with a higher rate of recanalization as well as a higher risk of bleeding, without benefits on survival or prevention of thrombosis recurrence.

  • Prediction of mortality in acute pulmonary embolism in cancer-associated thrombosis (MAUPE-C): derivation and validation of a multivariable model

    by Mario Aramberri, Jesús González-Olmedo, Adrián García-Villa, Ane Villanueva, Cristina Castillo Maza, Susana García-Gutiérrez, Carmen Diaz-Pedroche

    Optimal risk stratification of patients with cancer and pulmonary embolism (PE) remains unclear. We constructed a clinical prediction rule (CPR) named ‘MAUPE-C’ to identify patients with low 30 days mortality. The study retrospectively developed and internally validated a CPR for 30 days mortality in a cohort of patients with cancer and PE (both suspected and unsuspected). Candidate variables were chosen based on the EPIPHANY study, which categorized patients into 3 groups based on symptoms, signs, suspicion and patient setting at PE diagnosis. The performance of ‘MAUPE-C’ was compared to RIETE and sPESI scores. Univariate analysis confirmed that the presence of symptoms, signs, suspicion and inpatient diagnosis were associated with 30 days mortality. Multivariable logistic regression analysis led to the exclusion of symptoms as predictive variable. ‘MAUPE-C’ was developed by assigning weights to risk factors related to the β coefficient, yielding a score range of 0 to 4.5. After receiver operating characteristic (ROC) curve analysis, a cutoff point was established at ≤ 1. Prognostic accuracy was good with an area under the curve (AUC) of 0.77 (95% CI 0.71–0.82), outperforming RIETE and sPESI scores in this cohort (AUC of 0.64 [95% CI 0.57–0.71] and 0.57 [95% CI 0.49–0.65], respectively). Forty-five per cent of patients were classified as low risk and experienced a 2.79% 30 days mortality. MAUPE-C has good prognostic accuracy in identifying patients at low risk of 30 days mortality. This CPR could help physicians select patients for early discharge.


  • Cancer-associated splanchnic vein thrombosis: Clinical features upon diagnosis and short-term outcomes

    by Adrián García-Villa, Juan José Criado-Álvarez, María Carnevali, Mario Aramberri, Carme Font, Carmen Díaz-Pedroche


  • Open Access

    Saddle Pulmonary Embolism in Patients with Cancer in the Era of Incidental Events: Clinical Findings and Outcomes in a Single Centre Cohort

    by Mario Aramberri, Mariana Benegas, Marcelo Sanchez, Diego Muñoz-Guglielmetti, Carles Zamora, Adrián García-Villa, Carmen Diaz-Pedroche, Carme Font

    Background There is scarce information regarding the prevalence and clinical impact of saddle pulmonary embolism (PE) in patients with cancer. Objectives This study aimed to assess the prevalence, clinical findings, and short-term outcomes of patients with cancer-related saddle PE including acute symptomatic and unsuspected events. Patients/Methods Consecutive patients with cancer-related PE (March 1, 2006–October 31, 2014) were retrospectively reviewed by a chest radiologist to assess PE burden and signs of right ventricular (RV) overload. The clinical outcomes within 30 days were evaluated according to saddle versus nonsaddle PE. Results Thirty-six (12%) out of 289 patients with newly diagnosed cancer-related PE presented with saddle PE. Saddle PE was found in 21 cases (58%) with acute symptomatic PE and the remaining 15 cases (42%) were found as unsuspected findings. Patients with saddle PE had more frequently experienced a previous thrombotic event (31 vs. 13%; p=0.008), and it occurred more frequently as an acute symptomatic event (58 vs. 39%; p=0.025) compared with those with nonsaddle PE. Signs of RV overload including RV/left ventricle ratio ≥1 (22 vs. 4%; p<0.001) and interventricular septum displacement (53 vs. 20%; p<0.001) were also more common in patients with saddle PE compared with nonsaddle PE. Overall, PE-related mortality, venous thromboembolism recurrence, and major bleeding within 30 days were found to be similar according to saddle versus nonsaddle PE. Conclusion Saddle PE is not uncommon in patients with cancer-related PE including in those with unsuspected PE. Similar 30-day outcomes were found according to saddle versus nonsaddle PE in our cohort.


  • Open Access

    Saddle Pulmonary Embolism in Patients with Cancer in the Era of Incidental Events: Clinical Findings and Outcomes in a Single Centre Cohort

    by Mario Aramberri, Mariana Benegas, Marcelo Sanchez, Diego Muñoz-Guglielmetti, Carles Zamora, Adrián García-Villa, Carmen Diaz-Pedroche, Carme Font

    Background There is scarce information regarding the prevalence and clinical impact of saddle pulmonary embolism (PE) in patients with cancer. Objectives This study aimed to assess the prevalence, clinical findings, and short-term outcomes of patients with cancer-related saddle PE including acute symptomatic and unsuspected events. Patients/Methods Consecutive patients with cancer-related PE (March 1, 2006–October 31, 2014) were retrospectively reviewed by a chest radiologist to assess PE burden and signs of right ventricular (RV) overload. The clinical outcomes within 30 days were evaluated according to saddle versus nonsaddle PE. Results Thirty-six (12%) out of 289 patients with newly diagnosed cancer-related PE presented with saddle PE. Saddle PE was found in 21 cases (58%) with acute symptomatic PE and the remaining 15 cases (42%) were found as unsuspected findings. Patients with saddle PE had more frequently experienced a previous thrombotic event (31 vs. 13%; p = 0.008), and it occurred more frequently as an acute symptomatic event (58 vs. 39%; p = 0.025) compared with those with nonsaddle PE. Signs of RV overload including RV/left ventricle ratio ≥1 (22 vs. 4%; p < 0.001) and interventricular septum displacement (53 vs. 20%; p < 0.001) were also more common in patients with saddle PE compared with nonsaddle PE. Overall, PE-related mortality, venous thromboembolism recurrence, and major bleeding within 30 days were found to be similar according to saddle versus nonsaddle PE. Conclusion Saddle PE is not uncommon in patients with cancer-related PE including in those with unsuspected PE. Similar 30-day outcomes were found according to saddle versus nonsaddle PE in our cohort.


  • Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: A case report

    by Paula Lucía Villalba-Cuesta, Carmen Álvaro-Vegue, Carlos Girado Carrasco-Muñoz, Carmen Gomis-Goti, Adrián García-Villa

    Introduction: Androgen deprivation therapy remains the essential treatment for disseminated prostate cancer. Interstitial pneumonitis following this therapy has been documented for just a few cases. However, reported cases frequently describe the onset of symptoms after recent administration (days or a few weeks) of both GnRH analogues and androgen antagonists, which makes the precise individual impact of each treatment difficult to estimate. Case report: This report presents a case of a 94-year-old patient with interstitial pneumonitis whose onset started three months after the first dose of leuprorelin and bicalutamide for a metastatic prostate cancer. Management and outcome: Once other possible diagnosis were ruled out, empiric corticosteroid treatment was initiated within 48 h of the admission. A spectacular clinical and radiological improvement was observed after 3 doses of steroids, enabling the patient to recover his basal respiratory situation. We considered that the most probable cause was toxic interstitial pneumonitis induced by leuprorelin. Discussion: To our knowledge, it describes the longest interval between last administration of antiandrogen therapy and the development of pneumonitis. This fact may support a direct relation with leuprorelin, whose serum levels remain high for months because of its long-acting depot formulation.